We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Advances in cancer treatment
- Increasing numbers of cancer survivors
- The scope of the problem
- Etiology of cancer pain
- Causes of pain in people with cancer
- “Silver tsunami”
- An aging world
- Increasing survivors of cancer
- Who is a cancer survivor?
- Cancer care pathway
- What makes cancer pain different?
- Cancer survivors and pain
- Tumor- and treatment-related pain
- Reasons for classifying cancer-related pain
- Chronic pain syndromes associated with chemotherapy
- Chemotherapeutic agents known to cause neuropathy
- Diagnostic criteria
- Chronic pain syndromes associated with hormonal therapies
- Prevalence of AI arthralgia
- Chronic pain syndromes associated with radiation
- Chronic pain syndromes associated with stem cell transplant
- Painful signs and symptoms of chronic GVHD
- Chronic pain syndromes associated with surgery
- Immunotherapy
- How do we manage cancer pain while reducing harm?
- Pain in cancer survivors
- Those at risk of overtreatment
- Assessment
- Universal precautions
- Urine toxicology
- Universal precautions in pain management
- When opioids are no longer beneficial: weaning
- Summary
- Thank you!
Topics Covered
- Trends in cancer pain
- Etiology of cancer pain
- Cancer survivors
- Problems faced by cancer survivors who have persistent pain
- Tumor and treatment related pain
- Chronic pain syndromes associated with cancer treatment
- Guidelines for treating cancer survivors who experience persistent pain
- Challenges in managing pain associated with malignancies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Paice, J. (2021, July 29). Cancer pain [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 8, 2024, from https://doi.org/10.69645/ZNXE8042.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Judith Paice has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Judith Paice,
I'm the Director of the Cancer Pain Program in
the Division of Hematology-Oncology at Northwestern University,
in the Feinberg School of Medicine, located in Chicago.
Today's topic is cancer pain.
0:18
We're going to talk about some trends in cancer pain, that have resulted
because of some fantastic advancements that we've been seeing in oncology treatment.
We're going to recognize the problems faced by
a cancer survivors who, more and more often, are experiencing persistent pain.
We're going to discuss evolving challenges as we manage pain associated with malignancies.
0:46
A brief history: starting in the early 1900s (not really that terribly long ago),
we had very few treatment options for people with cancer,
primarily surgery or some very rudimentary radiotherapy.
In the early 1940s, actually as a result of soldiers handling mustard gas,
some interesting observations were made in the reduction of the lymphatic tissues
seen in these soldiers, and clever scientists put that
together to identify that nitrogen mustard may be
an effective treatment for lymphomas.
This was indeed responsible for reducing the size of these lymphoma tumors,
however, the results were not sustained.
But that began the early phase of chemotherapy, and we saw an advance in the 50s with
the introduction of 5-fluorouracil, methotrexate, and
the beginning of hormonal therapy for breast and prostate cancers.
In the 60s, people began to dream about the potential for cure, and we achieved
that through cure of some of the liquid tumors, like leukemias and Hodgkin's disease.
In the 70s we saw the cure of the first solid tumors, and this was the testicular cancers.
Some really amazing advancements in a relatively short period of time.
Then we really hit the accelerator, and saw
the first introduction of monoclonal antibodies that were approved,
agents such as rituximab, trastuzumab, and our first tyrosine kinase inhibitors were approved.
In the 2000s, now we are seeing immune system modulators, checkpoint inhibitors,
and more recently, therapies called CAR T,
where we are modifying the patient's own immune system.
Those advancements have led to amazing survival rates.